Thus, together with our previous report describing the prohypertrophic function of the PCAF in cardiomyocytes [24], our findings lead us to conclude that the PCAF plays dual roles to induce cardiac remodeling and that the modulation of PCAF signaling may provide a therapeutic platform to overcome adverse cardiac remodeling following cardiovascular diseases. Here, KAT2B is linked to cardiovascular disorder.